Scholar Rock (SRRK) Stock Forecast, Price Target & Predictions
SRRK Stock Forecast
Scholar Rock stock forecast is as follows: an average price target of $29.50 (represents a 267.37% upside from SRRK’s last price of $8.03) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
SRRK Price Target
The average price target for Scholar Rock (SRRK) is $29.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $31.00 to $28.00. This represents a potential 267.37% upside from SRRK's last price of $8.03.
SRRK Analyst Ratings
According to 3 Wall Street analysts, Scholar Rock's rating consensus is 'Buy'. The analyst rating breakdown for SRRK stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Scholar Rock Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 13, 2024 | Etzer Darout | BMO Capital | $31.00 | $9.39 | 230.14% | 286.05% |
| May 23, 2024 | Allison Bratzel | Piper Sandler | $28.00 | $11.18 | 150.45% | 248.69% |
| May 23, 2024 | Etzer Darout | BMO Capital | $29.00 | $11.18 | 159.39% | 261.15% |
The latest Scholar Rock stock forecast, released on Jun 13, 2024 by Etzer Darout from BMO Capital, set a price target of $31.00, which represents a 230.14% increase from the stock price at the time of the forecast ($9.39), and a 286.05% increase from SRRK last price ($8.03).
Scholar Rock Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $31.00 | $29.33 |
| Last Closing Price | $8.03 | $8.03 | $8.03 |
| Upside/Downside | -100.00% | 286.05% | 265.26% |
In the current month, the average price target of Scholar Rock stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Scholar Rock's last price of $8.03. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 09, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Jun 13, 2024 | BMO Capital | Outperform | Outperform | Hold |
| May 23, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 23, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Oct 24, 2023 | Jefferies | - | Buy | Upgrade |
| May 16, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Scholar Rock's last stock rating was published by BMO Capital on Aug 09, 2024. The company gave SRRK a "Outperform" rating, the same as its previous rate.
Scholar Rock Financial Forecast
Scholar Rock Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $33.19M | - | $5.46M | $4.59M | $4.71M | $3.44M | $3.04M | $3.90M | $5.03M | $7.57M | $4.77M | $5.04M | $3.11M |
| Avg Forecast | $8.78M | $3.17M | $8.07M | $2.11M | - | - | - | - | - | $22.13M | $4.40M | $4.64M | $5.20M | $6.00M | $6.51M | $7.63M | $6.85M | $24.81M | $5.19M | $9.11M | $5.28M | $4.77M |
| High Forecast | $8.78M | $3.17M | $8.07M | $2.11M | - | - | - | - | - | $22.13M | $4.40M | $4.64M | $5.20M | $6.00M | $6.51M | $7.63M | $6.85M | $24.81M | $5.19M | $9.11M | $5.28M | $4.77M |
| Low Forecast | $8.78M | $3.17M | $8.07M | $2.11M | - | - | - | - | - | $22.13M | $4.40M | $4.64M | $5.20M | $6.00M | $6.51M | $7.63M | $6.85M | $24.81M | $5.19M | $9.11M | $5.28M | $4.77M |
| # Analysts | - | - | - | - | - | - | - | 5 | 7 | 3 | 4 | 5 | 6 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.50% | - | 1.18% | 0.88% | 0.78% | 0.53% | 0.40% | 0.57% | 0.20% | 1.46% | 0.52% | 0.95% | 0.65% |
Scholar Rock's average Quarter revenue forecast for Dec 23 based on 7 analysts is -, with a low forecast of -, and a high forecast of -. SRRK's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $33.19M (Mar 22).
Scholar Rock EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 5 | 7 | 3 | 4 | 5 | 6 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | $-47.36M | $-6.18M | $-34.64M | $-36.83M | $-30.07M | $-27.08M | $-26.25M | $-23.17M | $-18.89M | $-16.68M | $-11.19M | $-16.31M | $-11.96M | $-10.24M |
| Avg Forecast | $-5.27M | $-1.90M | $-4.84M | $-1.27M | - | - | - | - | - | $-13.28M | $-2.64M | $-29.47M | $-27.76M | $-24.76M | $-3.91M | $-15.02M | $-15.04M | $-405.30M | $-3.12M | $-12.85M | $-9.92M | $-11.88M |
| High Forecast | $-5.27M | $-1.90M | $-4.84M | $-1.27M | - | - | - | - | - | $-13.28M | $-2.64M | $-23.57M | $-22.21M | $-19.81M | $-3.91M | $-12.02M | $-12.03M | $-324.24M | $-3.12M | $-10.28M | $-7.94M | $-9.50M |
| Low Forecast | $-5.27M | $-1.90M | $-4.84M | $-1.27M | - | - | - | - | - | $-13.28M | $-2.64M | $-35.36M | $-33.31M | $-29.71M | $-3.91M | $-18.03M | $-18.05M | $-486.36M | $-3.12M | $-15.42M | $-11.90M | $-14.25M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.47% | 13.11% | 1.25% | 1.08% | 1.09% | 6.72% | 1.54% | 1.26% | 0.04% | 3.59% | 1.27% | 1.21% | 0.86% |
undefined analysts predict SRRK's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Scholar Rock's previous annual EBITDA (undefined) of $NaN.
Scholar Rock Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 5 | 7 | 3 | 4 | 5 | 6 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 5 |
| Net Income | - | - | - | - | - | - | - | - | $-46.13M | $-8.97M | - | $-37.51M | $-30.71M | $-27.67M | $-26.57M | $-23.56M | $-19.28M | $-17.07M | $-11.57M | $-16.15M | $-12.53M | $-10.76M |
| Avg Forecast | $-46.66M | $-52.09M | $-54.80M | $-56.54M | $-55.18M | $-56.39M | $-57.16M | $-46.34M | $-35.43M | $-43.31M | $-75.11M | $-30.01M | $-28.34M | $-25.30M | $-46.35M | $-15.27M | $-15.35M | $-414.80M | $-42.09M | $-12.72M | $-10.39M | $-12.48M |
| High Forecast | $-46.66M | $-52.09M | $-54.80M | $-56.54M | $-55.18M | $-50.94M | $-57.16M | $-46.34M | $-32.54M | $-43.31M | $-75.11M | $-24.00M | $-22.68M | $-20.24M | $-46.35M | $-12.22M | $-12.28M | $-331.84M | $-42.09M | $-10.18M | $-8.31M | $-9.98M |
| Low Forecast | $-46.66M | $-52.09M | $-54.80M | $-56.54M | $-55.18M | $-59.12M | $-57.16M | $-46.34M | $-39.05M | $-43.31M | $-75.11M | $-36.01M | $-34.01M | $-30.36M | $-46.35M | $-18.33M | $-18.42M | $-497.76M | $-42.09M | $-15.27M | $-12.46M | $-14.97M |
| Surprise % | - | - | - | - | - | - | - | - | 1.30% | 0.21% | - | 1.25% | 1.08% | 1.09% | 0.57% | 1.54% | 1.26% | 0.04% | 0.27% | 1.27% | 1.21% | 0.86% |
Scholar Rock's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SRRK's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Scholar Rock SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 5 | 7 | 3 | 4 | 5 | 6 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 5 |
| SG&A | - | - | - | - | - | - | - | - | $13.07M | $10.76M | $10.36M | $11.28M | $9.27M | $9.37M | $7.76M | $8.27M | $6.37M | $5.82M | $5.86M | $6.18M | $4.71M | $4.07M |
| Avg Forecast | $12.80M | $4.62M | $11.76M | $3.08M | - | - | - | - | - | $32.25M | $6.42M | $6.76M | $7.58M | $8.75M | $9.49M | $5.36M | $5.07M | $36.16M | $7.57M | $4.87M | $3.91M | $4.72M |
| High Forecast | $12.80M | $4.62M | $11.76M | $3.08M | - | - | - | - | - | $32.25M | $6.42M | $6.76M | $7.58M | $8.75M | $9.49M | $6.43M | $6.08M | $36.16M | $7.57M | $5.84M | $4.69M | $5.67M |
| Low Forecast | $12.80M | $4.62M | $11.76M | $3.08M | - | - | - | - | - | $32.25M | $6.42M | $6.76M | $7.58M | $8.75M | $9.49M | $4.29M | $4.05M | $36.16M | $7.57M | $3.90M | $3.12M | $3.78M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.33% | 1.61% | 1.67% | 1.22% | 1.07% | 0.82% | 1.54% | 1.26% | 0.16% | 0.77% | 1.27% | 1.21% | 0.86% |
Scholar Rock's average Quarter SG&A projection for Mar 24 is -, based on 5 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to SRRK last annual SG&A of $13.07M (Dec 23).
Scholar Rock EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 5 | 7 | 3 | 4 | 5 | 6 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 5 |
| EPS | - | - | - | - | - | - | - | - | $-0.61 | $-0.24 | - | $-1.02 | $-0.84 | $-0.76 | $-0.89 | $-0.79 | $-0.65 | $-0.58 | $-0.39 | $-0.55 | $-0.48 | $-0.42 |
| Avg Forecast | $-0.48 | $-0.54 | $-0.57 | $-0.58 | $-0.57 | $-0.58 | $-0.59 | $-0.48 | $-0.47 | $-0.57 | $-0.99 | $-0.82 | $-0.75 | $-0.68 | $-0.61 | $-0.53 | $-0.52 | $0.01 | $-0.55 | $-0.31 | $-0.38 | $-0.48 |
| High Forecast | $-0.48 | $-0.54 | $-0.57 | $-0.58 | $-0.57 | $-0.53 | $-0.59 | $-0.48 | $-0.43 | $-0.57 | $-0.99 | $-0.82 | $-0.75 | $-0.68 | $-0.61 | $-0.53 | $-0.52 | $0.01 | $-0.55 | $-0.31 | $-0.38 | $-0.48 |
| Low Forecast | $-0.48 | $-0.54 | $-0.57 | $-0.58 | $-0.57 | $-0.61 | $-0.59 | $-0.48 | $-0.51 | $-0.57 | $-0.99 | $-0.82 | $-0.75 | $-0.68 | $-0.61 | $-0.53 | $-0.52 | $0.01 | $-0.55 | $-0.31 | $-0.38 | $-0.48 |
| Surprise % | - | - | - | - | - | - | - | - | 1.31% | 0.42% | - | 1.25% | 1.12% | 1.12% | 1.46% | 1.50% | 1.25% | -48.33% | 0.71% | 1.79% | 1.25% | 0.88% |
According to undefined Wall Street analysts, Scholar Rock's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SRRK previous annual EPS of $NaN (undefined).
Scholar Rock Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| PASG | Passage Bio | $0.70 | $6.00 | 757.14% | Buy |
| HOWL | Werewolf Therapeutics | $2.02 | $12.00 | 494.06% | Buy |
| SRRK | Scholar Rock | $8.03 | $29.50 | 267.37% | Buy |
| PLRX | Pliant Therapeutics | $12.87 | $40.50 | 214.69% | Buy |
| ARVN | Arvinas | $24.40 | $75.36 | 208.85% | Buy |
| RLAY | Relay Therapeutics | $6.24 | $18.13 | 190.54% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| BDTX | Black Diamond Therapeutics | $5.40 | $14.75 | 173.15% | Buy |
| IGMS | IGM Biosciences | $9.31 | $25.00 | 168.53% | Buy |
| MLYS | Mineralys Therapeutics | $11.23 | $30.00 | 167.14% | Buy |
| MGTX | MeiraGTx | $3.88 | $9.00 | 131.96% | Buy |
| STOK | Stoke Therapeutics | $14.70 | $33.33 | 126.73% | Buy |
| DSGN | Design Therapeutics | $4.67 | $9.67 | 107.07% | Buy |
| KROS | Keros Therapeutics | $52.51 | $105.00 | 99.96% | Buy |
| CGEM | Cullinan Oncology | $17.98 | $32.00 | 77.98% | Buy |
| IDYA | IDEAYA Biosciences | $36.21 | $45.50 | 25.66% | Buy |
| RNA | Avidity Biosciences | $40.46 | $50.00 | 23.58% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $41.84 | $51.20 | 22.37% | Buy |
| ANAB | AnaptysBio | $35.90 | $36.33 | 1.20% | Buy |
| IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
SRRK Forecast FAQ
Is Scholar Rock a good buy?
Yes, according to 3 Wall Street analysts, Scholar Rock (SRRK) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of SRRK's total ratings.
What is SRRK's price target?
Scholar Rock (SRRK) average price target is $29.5 with a range of $28 to $31, implying a 267.37% from its last price of $8.03. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Scholar Rock stock go up soon?
According to Wall Street analysts' prediction for SRRK stock, the company can go up by 267.37% (from the last price of $8.03 to the average price target of $29.5), up by 286.05% based on the highest stock price target, and up by 248.69% based on the lowest stock price target.
Can Scholar Rock stock reach $12?
SRRK's average twelve months analyst stock price target of $29.5 supports the claim that Scholar Rock can reach $12 in the near future.
What are Scholar Rock's analysts' financial forecasts?
Scholar Rock's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-215M (high $-210M, low $-218M), average SG&A $0 (high $0, low $0), and average EPS is $-2.226 (high $-2.17, low $-2.254). SRRK's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $22.13M (high $22.13M, low $22.13M), average EBITDA is $-13.278M (high $-13.278M, low $-13.278M), average net income is $-210M (high $-210M, low $-210M), average SG&A $32.25M (high $32.25M, low $32.25M), and average EPS is $-2.17 (high $-2.17, low $-2.17).
Did the SRRK's actual financial results beat the analysts' financial forecasts?
Based on Scholar Rock's last annual report (Dec 2021), the company's revenue was $18.82M, which missed the average analysts forecast of $20.24M by -7.06%. Apple's EBITDA was $-127M, beating the average prediction of $-84.627M by 50.42%. The company's net income was $-134M, missing the average estimation of $-159M by -15.80%. Apple's SG&A was $40.27M, beating the average forecast of $29.5M by 36.48%. Lastly, the company's EPS was $-3.64, beating the average prediction of $-3.232 by 12.61%. In terms of the last quarterly report (Mar 2022), Scholar Rock's revenue was $33.19M, beating the average analysts' forecast of $22.13M by 49.98%. The company's EBITDA was $-6.184M, missing the average prediction of $-13.279M by -53.43%. Scholar Rock's net income was $-8.967M, missing the average estimation of $-43.308M by -79.29%. The company's SG&A was $10.76M, missing the average forecast of $32.25M by -66.64%. Lastly, the company's EPS was $-0.24, missing the average prediction of $-0.57 by -57.89%